AdAPT-001 Mechanism of Action
As featured on
TORREY PINES, Calif., Sept. 29, 2021 /PRNewswire/ -- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today announced the completion of patient enrollment in the first cohort of a Phase 1 trial called BETA PRIME for its TGF-beta (TGFß) trap-enhanced cancer targeting adenovirus.
- Chastises Candidates for Voting Records
- NEW LIONS
- Urges Democrats to Vote for Manville
- WHS Girls Volleyball On a Roll: Exciting Indians Netting Wins
- Southbury School of Performing Arts Offers a Wide Range of Dance Classes
- Southbury Selectmen Approve Construction Bid for Curbing
- Supports Palomba for Board of Education
- ALUMNI CHECK
- Time for Action, Vote for Change
- Supports Diversity Efforts in Region 15
Sorry, there are no recent results for popular images.